Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IDAMYCIN PFS vs DAUNOXOME
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Idarubicin is an anthracycline antineoplastic antibiotic that intercalates with DNA and inhibits topoisomerase II, resulting in DNA strand breaks and inhibition of nucleic acid synthesis.
Daunorubicin intercalates between DNA base pairs, inhibiting topoisomerase II activity and preventing DNA replication and transcription. Liposomal encapsulation (Dauno Xome) alters distribution, reducing cardiotoxicity and enhancing tumor delivery.
Treatment of acute myeloid leukemia (AML) in adults,Treatment of acute lymphocytic leukemia (ALL) (off-label)
Treatment of advanced HIV-associated Kaposi sarcoma as first-line therapy,Acute myeloid leukemia (off-label),Acute lymphoblastic leukemia (off-label)
12 mg/m² intravenously over 10 to 15 minutes daily for 3 days (induction) or 12 mg/m² intravenously daily for 2 days (consolidation).
60-80 mg/m² intravenously over 1 hour every 2-4 weeks.
Terminal elimination half-life of idarubicin is 20-30 hours; idarubicinol (active metabolite) has a terminal half-life of 45-60 hours, extending myelosuppression duration.
Terminal elimination half-life is approximately 30-40 hours (range 20-48 h); prolonged compared to conventional doxorubicin due to liposomal encapsulation, allowing extended drug exposure.
Hepatic metabolism primarily via aldo-keto reductases to idarubicinol (active metabolite); further metabolism via glucuronidation.
Primarily hepatically metabolized via reduction to daunorubicinol by cytoplasmic reductases, and additionally by aldo-keto reductases and NADPH-dependent enzymes. Excretion: biliary and renal.
Renal (approximately 5-12% as unchanged drug and metabolites), biliary/fecal (significant, with 40-50% recovered in feces over 7 days).
Primarily biliary/fecal (40-50% as unchanged drug and metabolites); renal excretion accounts for approximately 5-15% as unchanged drug and metabolites over 5 days.
Idarubicin: 94-97% bound to plasma proteins (primarily albumin); idarubicinol: 90-95% bound.
Approximately 90-95% bound, primarily to plasma proteins (albumin); minimal displacement interactions reported.
Vd: 40-90 L/kg (extensive tissue distribution, indicating high affinity for intracellular sites such as DNA).
Vd is approximately 2-3 L/kg, indicating extensive tissue distribution; liposomal formulation concentrates in RES organs (liver, spleen) and tumors with leaky vasculature.
Oral bioavailability: approximately 30% (limited clinical use; idarubicin is typically administered IV).
Only administered intravenously; oral bioavailability is negligible (<5%) due to extensive first-pass metabolism and instability in GI tract.
GFR 20-50 m L/min: Administer 75% of dose; GFR <20 m L/min: Administer 50% of dose. Not dialyzable; no supplemental dose needed post-dialysis.
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) and consider dose reduction.
Child-Pugh Class B: Reduce dose by 25%; Child-Pugh Class C: Reduce dose by 50%. Severe hepatic dysfunction (bilirubin >3 mg/d L): Contraindicated unless benefit outweighs risk.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% or avoid use.
Children: 12 mg/m² intravenously daily for 3 days (induction) or 12 mg/m² daily for 2 days (consolidation). For infants <0.5 m²: 0.75 mg/kg intravenously daily for 3 days.
60-80 mg/m² intravenously over 1 hour every 2-4 weeks; safety and efficacy not established in children under 2 years.
No specific dose adjustment, but monitor for increased myelosuppression and cardiotoxicity. Consider dose reduction based on renal function and performance status.
No specific dose adjustment; monitor for increased toxicity due to age-related organ dysfunction.
Severe myelosuppression when used at therapeutic doses; cardiac toxicity including potentially fatal congestive heart failure, acute left ventricular failure, and arrhythmias; secondary malignancies including acute myeloid leukemia and myelodysplastic syndrome; extravasation leading to severe tissue necrosis; reduce dose in patients with hepatic impairment.
Dauno Xome should be administered under the supervision of a physician experienced in cancer chemotherapy. Severe myelosuppression occurs. Cardiac toxicity, including potentially irreversible cardiomyopathy, may occur, especially with cumulative doses >600 mg/m². Extravasation can cause severe tissue necrosis.
Monitor cardiac function before and during therapy; cumulative dose increases risk of cardiotoxicity,Severe myelosuppression with risk of infection and bleeding,Extravasation risk: administer via secure IV line,Secondary malignancies reported,Hepatic and renal impairment may require dose adjustment,Tumor lysis syndrome,May impair fertility
Monitor cardiac function (LVEF) regularly; cumulative dose limit 600 mg/m². Monitor blood counts for myelosuppression. Infusion reactions (hypotension, dyspnea) may occur. Not interchangeable with conventional daunorubicin.
Hypersensitivity to idarubicin or other anthracyclines,Severe hepatic impairment (Child-Pugh class C),Severe renal impairment (creatinine clearance < 30 m L/min),Pre-existing severe myelosuppression not due to leukemia,Severe cardiac dysfunction (e.g., recent myocardial infarction, cardiomyopathy)
Hypersensitivity to daunorubicin or any component of Dauno Xome. Severe hepatic impairment. Severe, pre-existing myelosuppression. Pregnancy (category D).
Avoid grapefruit and grapefruit juice due to potential CYP3A4 inhibition affecting drug metabolism. No other significant food interactions.
Avoid grapefruit and grapefruit juice due to potential CYP3A4 inhibition altering drug metabolism. No other significant food interactions. Maintain adequate hydration to prevent tumor lysis syndrome.
Idarubicin is embryotoxic and teratogenic in animal studies. Human data are limited, but it is classified as FDA Pregnancy Category D. There is evidence of fetal risk in the first trimester, including malformations and spontaneous abortion. In the second and third trimesters, there is risk of fetal growth restriction, preterm labor, and neonatal myelosuppression. Use only if potential benefit justifies risk.
Daunorubicin (Dauno Xome) is teratogenic in animal studies. First trimester: Avoid; major congenital malformations (cardiac, skeletal) reported. Second/third trimester: Use only if benefit outweighs risk; risk of fetal growth restriction, preterm birth, and neonatal myelosuppression. Fetal toxicity is dose-dependent.
It is unknown if idarubicin is excreted in human breast milk. Due to potential for serious adverse reactions in nursing infants, including immunosuppression and carcinogenesis, breastfeeding is contraindicated during treatment and for at least 1 month after the last dose. M/P ratio is not established.
Contraindicated during breastfeeding. Daunorubicin is excreted into human milk; M/P ratio not available. Potential for severe adverse reactions (immunosuppression, neutropenia, carcinogenesis) in the nursing infant. Advise to discontinue breastfeeding for at least 7-10 days after last dose.
No specific dose adjustments have been established for pregnancy. Physiological changes in pregnancy (increased plasma volume, altered hepatic metabolism) may affect pharmacokinetics but no formal studies exist. Use standard dosing based on body surface area with caution and monitor for toxicity.
No established dosing guidelines. Use lowest effective dose with standard body surface area calculations. Increased volume of distribution in pregnancy may require dose increase, but lack of safety data. Monitor for enhanced toxicity; consider dose reduction if severe myelosuppression or cardiotoxicity occurs.
Administer IV only; extravasation causes severe tissue necrosis. Premedicate with antiemetics. Monitor for cardiotoxicity with cumulative doses >550 mg/m2 (or 450 mg/m2 with prior chest irradiation). Urine may turn reddish for 1-2 days. Leukocyte nadir occurs 10-14 days after administration.
Dauno Xome (liposomal daunorubicin) has reduced cardiotoxicity compared to conventional daunorubicin due to preferential uptake by reticuloendothelial system. Cumulative lifetime dose limit is 600-800 mg/m² in adults (higher than conventional daunorubicin). Monitor for infusion reactions (flushing, dyspnea) especially during first dose. Myelosuppression is dose-limiting. Premedicate with antiemetics. Not interchangeable with conventional daunorubicin on mg/m² basis.
This drug can cause severe nausea and vomiting; take antiemetics as prescribed.,Your urine may appear red or orange for 1-2 days after treatment; this is normal.,Report any pain, redness, or swelling at the injection site immediately.,Avoid receiving live vaccines during treatment and for 6 months after.,Use effective contraception during and for at least 6 months after therapy.
This medication may cause temporary hair loss, nausea, vomiting, and mouth sores.,Report any signs of infection (fever, chills) or unusual bleeding/bruising immediately.,Avoid grapefruit and grapefruit juice during treatment.,Use effective contraception during therapy and for 6 months after last dose.,Do not receive live vaccines during treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IDAMYCIN PFS vs DAUNOXOME, answered by our medical review team.
IDAMYCIN PFS is a Anthracycline Antineoplastic that works by Idarubicin is an anthracycline antineoplastic antibiotic that intercalates with DNA and inhibits topoisomerase II, resulting in DNA strand breaks and inhibition of nucleic acid synthesis.. DAUNOXOME is a Anthracycline Antineoplastic that works by Daunorubicin intercalates between DNA base pairs, inhibiting topoisomerase II activity and preventing DNA replication and transcription. Liposomal encapsulation (Dauno Xome) alters distribution, reducing cardiotoxicity and enhancing tumor delivery.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IDAMYCIN PFS and DAUNOXOME depend on the specific clinical indication. These are both Anthracycline Antineoplastic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IDAMYCIN PFS is: 12 mg/m² intravenously over 10 to 15 minutes daily for 3 days (induction) or 12 mg/m² intravenously daily for 2 days (consolidation).. The standard adult dose of DAUNOXOME is: 60-80 mg/m² intravenously over 1 hour every 2-4 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IDAMYCIN PFS and DAUNOXOME in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IDAMYCIN PFS is classified as Category C. Idarubicin is embryotoxic and teratogenic in animal studies. Human data are limited, but it is classified as FDA Pregnancy Category D. There is evidence of fetal risk in the first . DAUNOXOME is classified as Category C. Daunorubicin (DaunoXome) is teratogenic in animal studies. First trimester: Avoid; major congenital malformations (cardiac, skeletal) reported. Second/third trimester: Use only if . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.